<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nippon Shinyaku Co., Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/nippon-shinyaku-co-ltd</link>
    <description>Latest news and press releases for Nippon Shinyaku Co., Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 09 Sep 2025 11:13:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nippon-shinyaku-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d62136beedb30cb6fc2a72.webp</url>
      <title>Nippon Shinyaku Co., Ltd.</title>
      <link>https://6ix.com/company/nippon-shinyaku-co-ltd</link>
    </image>
    <item>
      <title>FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis</title>
      <link>https://6ix.com/company/nippon-shinyaku-co-ltd/news/fda-grants-fast-track-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis</link>
      <guid isPermaLink="true">https://6ix.com/company/nippon-shinyaku-co-ltd/news/fda-grants-fast-track-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis</guid>
      <pubDate>Tue, 09 Sep 2025 11:13:00 GMT</pubDate>
      <description>NS Pharma, Inc. (NS Pharma) a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that the U.S Food &amp; Drug Administration (FDA) has granted Fast Track designation to NS-229, which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis (EGPA). NS-229 is being investigated as a selective Janus kinase 1 (JAK1) inhibitor to help regulate immune cell function and prevent the immune system from causing tissue damage.</description>
    </item>
    <item>
      <title>NS Pharma Announces Strategic Alliance with Boston Children&apos;s Hospital to Develop New Therapies for Rare Diseases</title>
      <link>https://6ix.com/company/nippon-shinyaku-co-ltd/news/ns-pharma-announces-strategic-alliance-with-boston-childrens-hospital-to-develop-new-therapies-for-rare-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/nippon-shinyaku-co-ltd/news/ns-pharma-announces-strategic-alliance-with-boston-childrens-hospital-to-develop-new-therapies-for-rare-diseases</guid>
      <pubDate>Tue, 01 Jul 2025 13:13:00 GMT</pubDate>
      <description>NS Pharma, Inc. (NS Pharma) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), headquartered in Kyoto, Japan, has finalized a strategic partnership with Boston Children&apos;s Hospital (Boston Children&apos;s) (Headquarters: Boston, Massachusetts, United States), to support the research and development of innovative therapies for rare diseases. Nippon Shinyaku and Boston Children&apos;s will leverage their combined expertise in clinical research and pharmaceutical development</description>
    </item>
  </channel>
</rss>